Perkins A, Izadpanah A, Sinno H, Bernard C, Williams Hb
Division of Plastic Surgery, McGill University, Montreal, Quebec.
Can J Plast Surg. 2011 Summer;19(2):e19-21.
The present article is a case report of a 16-year-old boy who presented with a benign bony tumour, which on histological analysis suggested giant cell reparative granuloma (GCRG), but was not corroborate by blood tests. The implications of this type of tumour and the correct diagnostic requirements were investigated. The correct identification of GCRG from other giant cell-containing tumours is important because the treatment modalities for these tumours significantly differ from one another. In most cases, histological findings are sufficient to identify the tumours. In most GCRG cases, curettage is usually a curative treatment option. However, due to high recurrence rates of GCRGs, close follow-up of these patients is warranted. Also, due to osteoclastic activity of the giant cells in GCRGs, the use of drugs such as calcitonin or bisphosphonates, which inhibit osteoclast differentiation and activation, may have an important influence on future treatments or in reducing the recurrence rate of these tumours.
本文是一篇关于一名16岁男孩的病例报告,该男孩患有良性骨肿瘤,组织学分析提示为巨细胞修复性肉芽肿(GCRG),但血液检查未证实。本文对这类肿瘤的影响及正确的诊断要求进行了研究。从其他含巨细胞的肿瘤中正确识别GCRG很重要,因为这些肿瘤的治疗方式差异很大。在大多数情况下,组织学检查结果足以识别肿瘤。在大多数GCRG病例中,刮除术通常是一种治愈性的治疗选择。然而,由于GCRG的复发率较高,对这些患者进行密切随访是必要的。此外,由于GCRG中巨细胞的破骨细胞活性,使用抑制破骨细胞分化和激活的药物,如降钙素或双膦酸盐,可能对未来的治疗或降低这些肿瘤的复发率有重要影响。